COMMUNIQUÉS West-GlobeNewswire

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
12/08/2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results [...]
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
12/08/2025
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public [...]
Quipt Home Medical Partners With Three Major Health Systems to Form Strategic Joint Venture
12/08/2025
Transaction Adds $60 Million in Revenue, 29 Locations, Deep Health System Relationships, and Marks Entry Into Michigan Market CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ [...]
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
12/08/2025
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company [...]
Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK
12/08/2025
CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® on-body drug delivery system, announced today that the [...]
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose [...]
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
12/08/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12, 2025 [...]
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
12/08/2025
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support [...]
57 Confluent Health Physical and Occupational Therapists Receive Board-Certified Clinical Specialist Credential
12/08/2025
Certification Reflects Highest Level of Advanced Clinical Practice in Musculoskeletal Care LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Fifty-seven Physical and Occupational Therapists from Confluent Health’s [...]
Hydreight Posts Record VSDHOne Growth, Ahead of 2025 Targets
12/08/2025
June and July orders surge; Perfect Scripts + 503B partnership boosts scale VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or [...]
Cerevance to Participate in Piper Sandler Virtual CNS Symposium
12/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today [...]
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
12/08/2025
In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ARD-201 was also associated with attenuated weight regain after discontinuation [...]
electroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga
12/08/2025
ROCKAWAY, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Kelly Benning has been hired as the Senior Vice [...]
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
12/08/2025
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for [...]
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
12/08/2025
Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5 [...]
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
12/08/2025
Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd [...]
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
12/08/2025
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by [...]
Counslr Launches in Schools Across the Country to Increase Mental Health Care Access
12/08/2025
Need For Alternative Models Grows in School Communities as Budget Cuts Reduce Student Mental Health Support NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Counslr , a leading mental health and wellness platform , announced [...]
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
12/08/2025
At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) [...]

Pages